Thrombin-activatable fibrinolysis inhibitor (TAFI, plasma procarboxypeptidase B, procarboxypeptidase R, procarboxypeptidase U)

Thrombosis Research

Volumn 101, Issue 5, 2001, Pages 329-354

  Bouma, Bonno N ^a,b   Marx, Pauline F ^a,b   Mosnier, Laurent O ^a,b   Meijers, Joost C M ^c  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b UTRECHT UNIVERSITY   (Netherlands)

^c ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

Carboxypeptidase; Coagulation; Fibrinolysis; TAFI

Indexed keywords

ARGININE CARBOXYPEPTIDASE; CARBOXYPEPTIDASE B; CARBOXYPEPTIDASE D; CARBOXYPEPTIDASE H; PROCARBOXYPEPTIDASE R; THROMBIN ACTIVATABLE FIBRINOLYSIS INHIBITOR; UNCLASSIFIED DRUG;

ARTICLE; BLOOD CLOTTING; DOWN REGULATION; ENZYME ANALYSIS; ENZYME BLOOD LEVEL; ENZYME SPECIFICITY; FIBRINOLYSIS; PANCREAS; PRIORITY JOURNAL; PROTEIN FAMILY;

ANIMALS; BLOOD COAGULATION; CARBOXYPEPTIDASE U; CARBOXYPEPTIDASES; FIBRINOLYSIS; HUMANS; LIVER; MODELS, BIOLOGICAL; THROMBIN;

EID: 0035279930     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0049-3848(00)00411-4     Document Type: Article

References (123)

1. Carboxypeptidase B: I. Purification of the zymogen and specificity of the enzyme
2. Radioimmunoassay of active pancreatic enzymes in sera from patients with acute pancreatitis: I. Active carboxypeptidase B
3. Three-dimensional structure of porcine procarboxypeptidase B: A structural basis of its inactivity
4. Mapping the pro-region of carboxypeptidase B by protein engineering - Cloning, overexpression, and mutagenesis of the porcine proenzyme
5. Analysis of the activation process of porcine procarboxypeptidase B and determination of the sequence of its activation segment
6. Crystal structure of the complex of carboxypeptidase A with a strongly bound phosphonate in a new crystalline form: Comparison with structures of other complexes
7. An enzyme in human blood plasma that inactivates bradykinin and kallidins
8. Basic carboxypeptidases: Regulators of peptide hormone activity
9. Human carboxypeptidase N: Lysine carboxypeptidase
10. Familial carboxypeptidase N deficiency
11. A labile enzyme in fresh human serum interferes with the assay of carboxypeptidase N
12. Characterisation of a carboxypeptidase in human serum distinct from carboxypeptidase N
13. Purification and characterization of a new arginine carboxypeptidase in human serum
14. An arginine specific carboxypeptidase generated in blood during coagulation or inflammation which is unrelated to carboxypeptidase N or its subunits
15. Isolation, molecular cloning, and partial characterization of a novel carboxypeptidase B from human plasma
16. Carboxypeptidase U, a plasma carboxypeptidase with high affinity for plasminogen
17. Purification and characterization of TAFI, a thrombin-activatable fibrinolysis inhibitor
18. Inactivation of active thrombin-activable fibrinolysis inhibitor takes place by a process that involves conformational instability rather than proteolytic cleavage
19. Activated protein C decreases plasminogen activator-inhibitor activity in endothelial cell-conditioned medium
20. Mechanism of protein C-dependent clot lysis: Role of plasminogen activator inhibitor
21. Protein C and fibrinolysis: A link between coagulation and fibrinolysis
22. The activated protein C-mediated enhancement of tissue-type plasminogen activator-induced fibrinolysis in a cell-free system
23. The effect of activated protein C on fibrinolysis in cell-free plasma can be attributed specifically to attenuation of prothrombin activation
24. The profibrinolytic effect of activated protein C in clots formed from plasma is TAFI-dependent
25. Plasma TAFI levels influence the clot lysis time in healthy individuals in the presence of an intact intrinsic pathway of coagulation
26. 2-macroglobulin and pregnancy zone protein
27. Activation and characterization of procarboxypeptidase B from human plasma
28. TAFI, or plasma procarboxypeptidase B, couples the coagulation and fibrinolytic cascades through the thrombin-thrombomodulin complex
29. Plasma and recombinant thrombin-activable fibrinolysis inhibitor (TAFI) and activated TAFI compared with respect to glycosylation, thrombin/thrombomodulin-dependent activation, thermal stability, and enzymatic properties
30. Activation of thrombin-activable fibrinolysis inhibitor requires epidermal growth factor-like domain 3 of thrombomodulin and is inhibited competitively by protein C
31. Characterization of plasmin-mediated activation of plasma procarboxypeptidase B - Modulation by glycosaminoglycans
32. Proteolytic activation of purified human procarboxypeptidase U
33. A carboxypeptidase inhibitor from the medical leech Hirudo medicinalis - Isolation, sequence analysis, cDNA cloning, recombinant expression, and characterization
34. Roles of thermal instability and proteolytic cleavage in regulation of activated thrombin-activable fibrinolysis inhibitor
35. Characterization of the gene encoding human TAFI (thrombin-activable fibrinolysis inhibitor; plasma procarboxypeptidase B)
36. Characterization of mouse thrombin-activatable fibrinolysis inhibitor
37. Procarboxypeptidase R is an acute phase protein in the mouse, whereas carboxypeptidase N is not
38. Molecular cloning and partial characterization of rat procarboxypeptidase B and carboxypeptidase N
39. The gene encoding human plasma carboxypeptidase R (CPB2) resides on chromosome 13
40. The gene for human carboxypeptidase U (CPU) - A proposed novel regulator of plasminogen activation - Maps to 13q-14.11
41. Plasma procarboxypeptidase U in men with symptomatic coronary artery disease
42. Identification and characterization of two thrombin-activatable fibrinolysis inhibitor isoforms
43. Activation of plasma procarboxypeptidase U in different mammalian species paints to a conserved pathway of inhibition of fibrinolysis
44. A baboon model can be used to assess the physiologic function of TAFI
45. Coagulation-dependent inhibition of fibrinolysis: Role of carboxypeptidase U and the premature lysis of clots from hemophilic plasma
46. Thrombin-activatable fibrinolysis inhibitor and the risk for deep vein thrombosis
47. Plasma carboxypeptidases as regulators of the plasminogen system
48. C-terminal lysine residues of fibrinogen fragments essential for binding to plasminogen
49. Characterization of the binding of plasminogen to fibrin surfaces: The role of carboxy-terminal lysines
50. Kinetics of the activation of plasminogen by human tissue plasminogen activator. Role of fibrin
51. Superficial accumulation of plasminogen during plasma clot lysis
52. A study of the mechanism of inhibition of fibrinolysis by activated thrombin-activable fibrinolysis inhibitor
53. Molecular mass dependence and the effect of TAFIa on the tPA and DSPA cofactor activities of soluble fibrin degradation products
54. Thrombin-activatable fibrinolysis inhibitor attenuates (DD)E-mediated stimulation of plasminogen activation by reducing the affinity of (DD)E for tissue plasminogen activator: A potential mechanism for enhancing fibrin specificity of tissue plasminogen activator
55. On the mechanism of the antifibrinolytic activity of plasma carboxypeptidase B
56. Factor XI deficiency in Ashkenazi Jews in Israel
57. Dental surgery in patients with severe factor XI deficiency without plasma replacement
58. Activation of human blood coagulation factor XI independent of factor XII. Factor XI is activated by thrombin and factor XIa in the presence of negatively charged surfaces
59. Factor XI activation in a revised model of blood coagulation
60. Feedback activation of factor XI by thrombin in plasma results in additional formation of thrombin that protects fibrin clots from fibrinolysis
61. Thrombin-mediated activation of factor XI results in a thrombin-activatable fibrinolysis inhibitor-dependent inhibition of fibrinolysis
62. A 10-kDa cyanogen bromide fragment from the epidermal growth factor homology domain of rabbit thrombomodulin contains the primary thrombin binding site
63. Elements of the primary structure of thrombomodulin required for efficient thrombin-activable fibrinolysis inhibitor activation
64. Thrombin interacts with thrombomodulin, protein C, and thrombin-activatable fibrinolysis inhibitor via specific and distinct domains
65. Structural basis for the anticoagulant activity of the thrombin-thrombomodulin complex
66. Solution structure of the smallest cofactor-active fragment of thrombomodulin
67. Regulation of fibrinolysis in plasma by TAFI and protein C is dependent on the concentration of thrombomodulin
68. The physiology and biochemistry of factor XIII
69. Assembly and activation of the intrinsic fibrinolytic pathway on the surface of human endothelial cells in culture
70. Inactivation of single-chain urokinase (pro-urokinase) by thrombin and thrombin-like enzymes: Relevance of the findings to the interpretation of fibrin-binding experiments
71. Activation with plasmin of two-chain urokinase-type plasminogen activator derived from single-chain urokinase-type plasminogen activator by treatment with thrombin
72. The inactivation of single-chain urokinase-type plasminogen activator by thrombin in a plasma milieu: Effect of thrombomodulin
73. The inactivation of single-chain urokinase-type plasminogen activator by thrombin may provide an additional explanation for the antifibrinolytic effect of factor XI
74. Factor XI dependent and independent activation of thrombin-activatable fibrinolysis inhibitor (TAFI) in plasma associated with clot formation
75. Plasma lipoproteins enhance tissue factor-independent factor VII activation
76. Increased fibrinolytic activity during use of oral contraceptives is counteracted by an enhanced factor XI-independent down regulation of fibrinolysis - A randomized cross-over study of two low-dose oral contraceptives
77. Factor XI and protection of the fibrin clot against lysis - A role for the intrinsic pathway of coagulation in fibrinolysis
78. Activation of factor IX by the reaction product of tissue factor and factor VII: Additional pathway for initiating blood coagulation
79. An alternative extrinsic pathway of human blood coagulation
80. The role of tissue factor pathway inhibitor in a revised coagulation cascade
81. Blood clotting in minimally altered whole blood
82. Activated human protein C prevents thrombin-induced thromboembolism in mice - Evidence that activated protein C reduces intravascular fibrin accumulation through the inhibition of additional thrombin generation
83. Mutation in blood coagulation factor V associated with resistance to activated protein C
84. Leiden
85. Blood coagulation - The thrombin paradox
86. Antithrombotic effects of thrombin-induced activation of endogenous protein C in primates
87. The pathophysiology of the prethrombotic state in humans: Insights gained from studies using markers of hemostatic system activation
88. Role of clotting factor VIII in effect of von Willebrand factor on occurrence of deep vein thrombosis
89. High levels of factor IX increase the risk of venous thrombosis
90. High levels of coagulation factor XI as a risk factor for venous thrombosis
91. Plasma TAFI antigen variations in healthy subjects
92. Assay of procarboxypeptidase U, a novel determinant of the fibrinolytic cascade, in human plasma
93. A novel approach to arterial thrombolysis
94. Enhancement of rabbit jugular vein thrombolysis by neutralization of factor XI - In vivo evidence for a role of factor XI as an anti-fibrinolytic factor
95. An inhibitor of activated thrombin-activatable fibrinolysis inhibitor potentiates tissue-type plasminogen activator-induced thrombolysis in a rabbit jugular vein thrombolysis model
96. Carboxypeptidase inhibitor from potatoes
97. Refolding of potato carboxypeptidase inhibitor by molecular dynamics stimulations with disulfide bond constraints
98. Expression of a synthetic gene encoding potato carboxypeptidase inhibitor using a bacterial secretion vector
99. Contribution of C-tail residues of potato carboxypeptidase inhibitor to the binding to carboxypeptidase A - A mutagenesis analysis
100. Inhibition of radiation-induced transformation of C3H/10T1/2 cells by carboxypeptidase inhibitor I and inhibitor II from potatoes
101. Potato carboxypeptidase inhibitor, a T-knot protein, is an epidermal growth factor antagonist that inhibits tumor cell growth
102. An arginine carboxypeptidase generated during coagulation is diminished or absent in patients with rheumatoid arthritis
103. Plasma thrombomodulin in health and disease
104. Thrombomodulin in human plasma contributes to inhibit fibrinolysis through acceleration of thrombin-dependent activation of plasma procarboxypeptidase B
105. Protein C activation on endothelial cells by prothrombin activation products generated in situ: Meizothrombin is a better protein C activator than a-thrombin
106. Serial studies of protein C and its plasma inhibitor in patients with disseminated intravascular coagulation
107. Oxidation of a specific methionine in thrombomodulin by activated neutrophil products blocks cofactor activity. A potential rapid mechanism for modulation of coagulation
108. Reduced activity of TAFI (thrombin-activatable fibrinolysis inhibitor) in acute promyelocytic leukaemia
109. Comparison of sustained antithrombotic effects of inhibitors of thrombin and factor Xa in experimental thrombosis
110. Inducible carboxypeptidase activity - A role in clot lysis in vivo
111. Levels of carboxypeptidase B (thrombin-activatable fibrinolysis inhibitor, TAFI) following thrombolysis with streptokinase
112. Consequences of inhibition of plasma carboxypeptidase B on in vivo thrombolysis, thrombosis and hemostasis
113. Carboxypeptidase B
114. Lysine carboxypeptidase
115. Cellular carboxypeptidases
116. Metallocarboxypeptidase D
117. Carboxypeptidase E/H
118. Purification and characterization of human metallocarboxypeptidase Z
119. Cloning and expression of human carboxypeptidase Z, a novel metallocarboxypeptidase
120. A eukaryotic transcriptional repressor with carboxypeptidase activity
121. Enzymic characterization of a novel member of the regulatory B-like carboxypeptidase with transcriptional repression function: Stimulation of enzymic activity by its target DNA
122. Carboxypeptidase U